Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity

Summary

Akari Therapeutics CEO discusses the company's positioning in the growing market for next-generation antibody-drug conjugate (ADC) payloads for oncology applications. The article focuses on management commentary regarding industry demand rather than reporting specific clinical, financial, or regulatory events.